Article
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
The Journal of clinical investigation - 1 Aug 2016
Drost Rinske, Dhillon Kiranjit K, van der Gulden Hanneke, van der Heijden Ingrid, Brandsma Inger, Cruz Cristina, Chondronasiou Dafni, Castroviejo-Bermejo Marta, Boon Ute, Schut Eva, van der Burg Eline, Wientjens Ellen, Pieterse Mark, Klijn Christiaan, Klarenbeek Sjoerd, Loayza-Puch Fabricio, Elkon Ran, van Deemter Liesbeth, Rottenberg Sven, van de Ven Marieke, Dekkers Dick H W, Demmers Jeroen A A, van Gent Dik C, Agami Reuven, Balmaña Judith, Serra Violeta, Taniguchi Toshiyasu, Bouwman Peter, Jonkers Jos
Abstract excerpt
Heterozygous germline mutations in breast cancer 1 (BRCA1) strongly predispose women to breast cancer. BRCA1 plays an important role in DNA double-strand break (DSB) repair via homologous recombination (HR), which is important for tumor suppression. Although BRCA1-deficient cells are highly sensitive to treatment with DSB-inducing agents through their HR deficiency (HRD), BRCA1-associated tumors display...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.